Jenscare Scientific Co. Ltd. Class H (HK:9877)
:9877
Want to see HK:9877 full AI Analyst Report?
9877 Stock Chart & Stats
HK$9.48
HK$0.16(3.97%)
At close: 4:00 PM EST
HK$9.48
HK$0.16(3.97%)
Day’s Range― - ―
52-Week RangeHK$7.04 - HK$11.98
Previous CloseN/A
Volume216.80K
Average Volume (3M)805.10K
Market Cap
HK$4.59B
Enterprise ValueHK$2.48B
Total Cash (Recent Filing)HK$527.63M
Total Debt (Recent Filing)HK$47.38M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding310,306,200
10 Day Avg. Volume637,060
30 Day Avg. Volume805,099
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)4.22
Price to Sales (P/S)37.79
P/FCF Ratio-41.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)HK$261.02M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~75% gross margins indicate attractive unit economics for Jenscare's transcatheter devices. High product margins provide structural room to absorb SG&A and R&D while pursuing commercialization, enabling scalable profitability as volumes grow and fixed costs leverage down.
Revenue AccelerationA sharp revenue ramp in 2025 reflects initial commercial traction and adoption of the company’s structural heart products. Sustained top-line growth is a durable indicator of market acceptance and supports future operating leverage if management controls operating expense growth.
Low Financial LeverageVery low debt relative to equity provides balance-sheet flexibility during the commercialization phase. Minimal leverage reduces solvency risk, eases interest burdens, and increases options for funding growth (equity, partnerships, or modest debt) without acute refinancing pressure.
Bears Say
Large Net LossesA large, persistent net loss (~264M) shows the business is well short of profitability and implies years of operating deficits could continue. This magnitude of loss erodes equity, increases dependency on external funding, and lengthens the timeline to durable positive returns for shareholders.
Negative Free Cash FlowNegative FCF (≈-80M) means the company is consuming cash to operate and invest. Continued cash burn requires recurring financing, which can dilute shareholders or constrain strategic choices; this represents a structural funding risk until operations generate consistent positive cash flow.
Operating Costs Outstrip RevenueOperating expenses materially exceed current revenue, indicating the cost base is not yet aligned with commercialization scale. Unless expense growth is curtailed or revenue scales faster, the firm will remain unprofitable and vulnerable to funding cycles and dilution over multiple quarters.
Jenscare Scientific Co. Ltd. Class H News
9877 FAQ
What was Jenscare Scientific Co. Ltd. Class H’s price range in the past 12 months?
Jenscare Scientific Co. Ltd. Class H lowest stock price was HK$7.04 and its highest was HK$11.98 in the past 12 months.
What is Jenscare Scientific Co. Ltd. Class H’s market cap?
Jenscare Scientific Co. Ltd. Class H’s market cap is HK$4.59B.
When is Jenscare Scientific Co. Ltd. Class H’s upcoming earnings report date?
Jenscare Scientific Co. Ltd. Class H’s upcoming earnings report date is Sep 02, 2026 which is in 92 days.
How were Jenscare Scientific Co. Ltd. Class H’s earnings last quarter?
Jenscare Scientific Co. Ltd. Class H released its earnings results on Mar 26, 2026. The company reported -HK$0.29 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.29.
Is Jenscare Scientific Co. Ltd. Class H overvalued?
According to Wall Street analysts Jenscare Scientific Co. Ltd. Class H’s price is currently Overvalued.
Does Jenscare Scientific Co. Ltd. Class H pay dividends?
Jenscare Scientific Co. Ltd. Class H does not currently pay dividends.
What is Jenscare Scientific Co. Ltd. Class H’s EPS estimate?
Jenscare Scientific Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jenscare Scientific Co. Ltd. Class H have?
Jenscare Scientific Co. Ltd. Class H has 310,306,200 shares outstanding.
What happened to Jenscare Scientific Co. Ltd. Class H’s price movement after its last earnings report?
Jenscare Scientific Co. Ltd. Class H reported an EPS of -HK$0.29 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.222%.
Which hedge fund is a major shareholder of Jenscare Scientific Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9877
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jenscare Scientific Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
201.35%
12-Months-Change
Fundamentals
Return on Equity
-22.25%
Trailing 12-Months
Asset Growth
-8.72%
Trailing 12-Months
Company Description
Jenscare Scientific Co. Ltd. Class H
Jenscare Scientific Co., Ltd., a medical device company, engages in the research and development of invasive interventional therapies for structural heart diseases in the People's Republic of China. The company offers LuX-Valve, a transcatheter tricuspid valve replacement (TTVR) product candidate for the treatment of severe tricuspid regurgitation and high surgical risk; and Ken-Valve, a transcatheter aortic valve replacement product candidate for the treatment of severe aortic regurgitation or combined with aortic stenosis. Its products have applications in the treatment of structural heart diseases, including tricuspid valve diseases, aortic valve diseases, mitral valve diseases, and heart failure. The company was incorporated in 2011 and is headquartered in Ningbo, the People's Republic of China.
Technical Analysis
Peijia Medical Ltd.
―
LifeTech Scientific Corporation
―
Shanghai Kindly Medical Instruments Co., Ltd. Class H
―
AK Medical Holdings Ltd.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---